Clue to Aspirin, Colon Cancer Link; New Lutathera Approval; AI & Electronic Records

Possibly uncovering a clue to a longstanding mystery, Italian researchers found that aspirin may help prevent colorectal cancer by pointing the immune system toward cancer cells. (Cancer)

The FDA expanded indications for lutetium Lu 177 dotatate (Lutathera) to include pediatric patients with gastroenteropancreatic neuroendocrine tumors, Novartis announced.

Gilead Sciences will discontinue development of magrolimab, an anti-CD47 antibody, for hematologic malignancies. (BioSpace)

Amid slumping sales and stock prices, Roche will eliminate three developmental cancer programs. (Bloomberg)

Innate Pharma and 23andMe have joined forces to develop anticancer antibodies that target natural killer cells. (BioSpace)

The American Society of Clinical Oncology and the College of American Pathologists have called on manufacturers of diagnostic and therapeutic products to adopt “therapeutic group labeling” to improve access to effective therapies.

The University of Texas MD Anderson Cancer Center will extend its regional service facilities to Chicago in a partnership with RUSH University Health System.

St. Jude Children’s Research Hospital named Andrew Smith, MD, PhD, an authority on applying artificial intelligence to medical imaging, as head of diagnostic imaging.

Integrating AI into electronic messaging systems may help relieve physician burden and improve patient education but still requires a “physician in the loop” as a backstop for errors in messaging. (Mass General Brigham, The Lancet Digital Health)

The use of and survival for stem-cell transplants has increased across all racial and ethnic groups, although mortality remains higher among African Americans. (Blood Advances)

Contradicting conventional wisdom, a study suggests that normalizing tumor blood vessels and improving oxygen levels may enhance treatment effectiveness in preventing lung cancer progression. (Phoenix Children’s Hospital, EMBO Molecular Medicine)

Please enable JavaScript to view the

comments powered by Disqus.